Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02687854 · ClinicalTrials.gov registry record
Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 18,591
- Enrollment target
NCT02687854: Completed study, sponsored by Bayer.
NCT02687854 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 18,591 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02687854 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 18,591 participants
- Enrollment target
Study Summary
To obtain a better understanding on the comparative effectiveness of apixaban versus VKA (Vitamin K antagonist) for stroke prevention in patients with NVAF (Non-valvular atrial fibrillation) in a real-life setting.
Interventions
- DRUG Apixaban
- DRUG Vitamin K antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,591 participants |
| Start Date | 2016-02-12 |
| Est. Completion | 2016-03-01 |
What the finished NCT02687854 record still lists
NCT02687854 is an observational study that tracks outcomes without assigning an intervention. Its 18,591 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Apixaban is the first listed.
NCT02687854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02687854 about?
NCT02687854 is a clinical study titled "Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist". To obtain a better understanding on the comparative effectiveness of apixaban versus VKA (Vitamin K antagonist) for stroke prevention in patients with NVAF (Non-valvular atrial fibrillation) in a real-life setting.
What is the current status of trial NCT02687854?
This trial is currently completed. The enrollment target is 18,591 participants. The study started on 2016-02-12. Estimated completion is 2016-03-01.
What interventions are being tested in trial NCT02687854?
The interventions under investigation include: Apixaban (DRUG), Vitamin K antagonist (DRUG).
Who is sponsoring clinical trial NCT02687854?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
- NCT05513833 · 18,000 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky
- NCT06802224 · 18,000 participants · Phase 4
The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI